4:13 PM
 | 
Nov 15, 2018
 |  BC Extra  |  Financial News

V-Bio, Gimv lead €37M Camel-IDS series A

Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A round to support Phase II trials of lead brain metastatic breast cancer candidate, CAM-H2. V-Bio Ventures and Gimv led the round, which included co-lead investors HealthCap Advisor AB, Novo Seeds, Pontifax and BioMedPartners.

Camel-IDS CEO Ruth Devenyns told...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >